AR063101A1 - Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. - Google Patents
Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.Info
- Publication number
- AR063101A1 AR063101A1 ARP070104363A ARP070104363A AR063101A1 AR 063101 A1 AR063101 A1 AR 063101A1 AR P070104363 A ARP070104363 A AR P070104363A AR P070104363 A ARP070104363 A AR P070104363A AR 063101 A1 AR063101 A1 AR 063101A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- group
- formula
- heterocyclic ring
- chosen
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000003725 azepanyl group Chemical group 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003884 phenylalkyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los compuestos son utiles para el tratamiento y/o profilaxis de enfermedades asociadas con la modulacion de receptores del CB2. Se proveen además, composiciones farmacéuticas que los contienen. Reivindicacion 1: Compuestos de la formula general (1) en la que se elige entre el grupo formado por alquilo inferior, hidroxialquilo inferior, cicloalquilo que está sin sustituir o sustituido con un grupo elegido entre hidroxi, alcoxi inferior e hidroxialquilo inferior, cicloalquilalquilo inferior, heterociclilalquilo inferior, -CR5R6-COOR7 y -CR5R6-CONH2; R5 y R6 con independencia entre sí son hidrogeno o alquilo inferior; R7 es alquilo inferior; R2 es hidrogeno; o R1 y R2 junto con el átomo de nitrogeno al que están unidos forman un anillo heterocíclico de 4, 5, 6 o 7 eslabones que contiene opcionalmente otro heteroátomo elegido entre nitrogeno, oxígeno o azufre; uno de R3 o R4 se elige entre el grupo formado por alquilamino inferior, di(alquilo inferior)amino, cicloalquilamino.y halogenofenilo, o es un anillo heterocíclico elegido entre azetidinilo, pirrolidinilo, piperidinilo, morfolinilo, tiomorfolinilo y azepanilo, dicho anillo heterocíclico está sin sustituir o sustituido con halogeno; y el otro de R3 o R4 es -OR8 o - NRR10, en los que R8 se elige entre el grupo formado por alquilo inferior, halogenoalquilo inferior, cicloalquilo, cicloalquilalquilo inferior, fenilalquilo inferior, dicho fenilo está sin sustituir o sustituido con un grupo elegido entre alquilo inferior, alcoxi inferior y halogeno, heterociclilalquilo inferior, heteroarilalquilo inferior, alcoxialquilo inferior e hidroxialquilo inferior; R9 es alquilo inferior y R10 es alquilo inferior o alcoxialquilo inferior; o bien en el caso de que uno de R3 o R4 sea halogenofenilo, R9 y R10 junto con el átomo de nitrogeno al que están unidos pueden formar también un anillo heterocíclico elegido entre pirrolidinilo y piperidinilo; y sus sales farmacéuticamente aceptables. 19. Un proceso de obtencion de los compuestos de la formula 1 ya definida en una cualquiera de las reivindicaciones de 1 a 18, dicho proceso consiste en: hacer reaccionar un compuesto de la formula (2) en la que R3 y R4 tienen los significados definidos en la reivindicacion 1, con una amina de la formula H-NR1R2 en la que R1 y R2 tienen los significados definidos en la reivindicacion 1, con la intervencion de un agente de adicion, en condiciones básicas, y, si se desea, convertir el compuesto resultante de la formula 1 en una sal farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06121749 | 2006-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063101A1 true AR063101A1 (es) | 2008-12-30 |
Family
ID=39166552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104363A AR063101A1 (es) | 2006-10-04 | 2007-10-02 | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7691863B2 (es) |
| EP (1) | EP2076499B1 (es) |
| JP (1) | JP5064506B2 (es) |
| KR (1) | KR101114704B1 (es) |
| CN (1) | CN101522644B (es) |
| AR (1) | AR063101A1 (es) |
| AT (1) | ATE467622T1 (es) |
| AU (1) | AU2007304363B2 (es) |
| BR (1) | BRPI0717822A2 (es) |
| CA (1) | CA2664621A1 (es) |
| CL (1) | CL2007002834A1 (es) |
| DE (1) | DE602007006531D1 (es) |
| ES (1) | ES2344128T3 (es) |
| IL (1) | IL197763A0 (es) |
| MX (1) | MX2009003316A (es) |
| PE (1) | PE20080855A1 (es) |
| TW (1) | TW200825065A (es) |
| WO (1) | WO2008040649A2 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| AU2007304365A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
| US8088920B2 (en) | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
| US7897621B2 (en) | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| CN104837831B (zh) * | 2012-12-07 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 新的吡啶衍生物 |
| RS56424B1 (sr) * | 2012-12-07 | 2018-01-31 | Hoffmann La Roche | Piridin-2-amidi korisni kao cb2-agonisti |
| CA2885987A1 (en) * | 2012-12-07 | 2014-06-12 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| US9512141B2 (en) * | 2012-12-07 | 2016-12-06 | Hoffmann-La Roche Inc. | Pyrazine derivatives as CB2 receptor agonists |
| SG11201608246VA (en) * | 2014-04-04 | 2016-10-28 | Hoffmann La Roche | 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists |
| JP6751203B2 (ja) | 2016-06-07 | 2020-09-02 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． | Ｓｈｐ２阻害剤として有用な新規複素環式誘導体 |
| SG11201908820VA (en) | 2017-03-23 | 2019-10-30 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN109384734B (zh) * | 2017-08-14 | 2023-04-11 | 上海科胜药物研发有限公司 | 一种塞尔西帕中间体的制备方法 |
| EP3814337B1 (en) * | 2018-06-27 | 2025-05-14 | F. Hoffmann-La Roche AG | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| SG11202009103WA (en) * | 2018-06-27 | 2020-10-29 | Hoffmann La Roche | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| WO2020002314A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Radiolabeled cannabinoid receptor 2 ligand |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| WO2023082145A1 (en) * | 2021-11-11 | 2023-05-19 | 4B Technologies (Suzhou) Limited | Intermediate compound of quinoxaline and preparation process thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5738778A (en) * | 1980-08-18 | 1982-03-03 | Kyowa Gas Chem Ind Co Ltd | Novel cyanopyrazine derivative |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| JP4960085B2 (ja) * | 2003-03-19 | 2012-06-27 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| US20060135523A1 (en) * | 2003-06-18 | 2006-06-22 | Astrazeneca Ab | 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| ES2326280T3 (es) | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derivados de piridin-3-carboxamida como agonistas inversos de cb1. |
| US7629346B2 (en) * | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
-
2007
- 2007-09-24 ES ES07820497T patent/ES2344128T3/es active Active
- 2007-09-24 AT AT07820497T patent/ATE467622T1/de active
- 2007-09-24 CA CA002664621A patent/CA2664621A1/en not_active Abandoned
- 2007-09-24 KR KR1020097008997A patent/KR101114704B1/ko not_active Expired - Fee Related
- 2007-09-24 MX MX2009003316A patent/MX2009003316A/es active IP Right Grant
- 2007-09-24 CN CN2007800372430A patent/CN101522644B/zh not_active Expired - Fee Related
- 2007-09-24 US US11/903,581 patent/US7691863B2/en not_active Expired - Fee Related
- 2007-09-24 WO PCT/EP2007/060090 patent/WO2008040649A2/en not_active Ceased
- 2007-09-24 EP EP07820497A patent/EP2076499B1/en not_active Not-in-force
- 2007-09-24 DE DE602007006531T patent/DE602007006531D1/de active Active
- 2007-09-24 BR BRPI0717822-0A2A patent/BRPI0717822A2/pt not_active IP Right Cessation
- 2007-09-24 AU AU2007304363A patent/AU2007304363B2/en not_active Ceased
- 2007-09-24 JP JP2009530841A patent/JP5064506B2/ja not_active Expired - Fee Related
- 2007-10-02 TW TW096136934A patent/TW200825065A/zh unknown
- 2007-10-02 CL CL200702834A patent/CL2007002834A1/es unknown
- 2007-10-02 AR ARP070104363A patent/AR063101A1/es unknown
- 2007-10-03 PE PE2007001334A patent/PE20080855A1/es not_active Application Discontinuation
-
2009
- 2009-03-23 IL IL197763A patent/IL197763A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007304363A1 (en) | 2008-04-10 |
| AU2007304363B2 (en) | 2013-01-17 |
| WO2008040649A3 (en) | 2008-05-29 |
| CL2007002834A1 (es) | 2008-05-16 |
| TW200825065A (en) | 2008-06-16 |
| CN101522644B (zh) | 2013-04-24 |
| KR20090084842A (ko) | 2009-08-05 |
| EP2076499A2 (en) | 2009-07-08 |
| MX2009003316A (es) | 2009-04-09 |
| KR101114704B1 (ko) | 2012-03-14 |
| JP2010505788A (ja) | 2010-02-25 |
| ATE467622T1 (de) | 2010-05-15 |
| BRPI0717822A2 (pt) | 2013-11-12 |
| ES2344128T3 (es) | 2010-08-18 |
| DE602007006531D1 (de) | 2010-06-24 |
| US7691863B2 (en) | 2010-04-06 |
| CA2664621A1 (en) | 2008-04-10 |
| IL197763A0 (en) | 2009-12-24 |
| EP2076499B1 (en) | 2010-05-12 |
| CN101522644A (zh) | 2009-09-02 |
| US20080085905A1 (en) | 2008-04-10 |
| JP5064506B2 (ja) | 2012-10-31 |
| WO2008040649A2 (en) | 2008-04-10 |
| PE20080855A1 (es) | 2008-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| HUP0300693A2 (hu) | Eljárás epotilon-analógok és -intermedierek előállítására | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
| PE20231935A1 (es) | Moduladores de la via de estres integrada | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20110835A1 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
| TW200744587A (en) | Azaindole derivatives exhibiting PGD2 receptor antagonism | |
| NO20064366L (no) | Tiazolderivat | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR061642A1 (es) | Derivados de ureas de tropano, su preparacion y su aplicacion en terapeu-tica, procesos de obtencion y composiciones farmaceuticas | |
| PE20030440A1 (es) | Fenilsulfonamidas como antagonistas de ccr3 | |
| PE20050555A1 (es) | Compuestos con puente n-arilsulfonilpiperidina como inhibidores de la gamma-secretasa | |
| AR046085A1 (es) | Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico | |
| AR077440A1 (es) | Bencenosulfonamidas como bloqueadores de canales de calcio y composiciones farmaceuticas | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| CO6351734A2 (es) | Compuestos de amida utiles en terapia | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |